American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

BACKGROUND Venous thromboembolism (VTE) is the third most common vascular disease. Medical inpatients, long-term care residents, persons with minor injuries, and long-distance travelers are at increased risk. OBJECTIVE These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about preventing VTE in these groups. METHODS ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline-development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS The panel agreed on 19 recommendations for acutely ill and critically ill medical inpatients, people in long-term care facilities, outpatients with minor injuries, and long-distance travelers. CONCLUSIONS Strong recommendations included provision of pharmacological VTE prophylaxis in acutely or critically ill inpatients at acceptable bleeding risk, use of mechanical prophylaxis when bleeding risk is unacceptable, against the use of direct oral anticoagulants during hospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated compression stockings or low-molecular-weight heparin in long-distance travelers only if they are at high risk for VTE.

[1]  Gilbert GREUB,et al.  Venous thromboembolism in critically Ill patients with COVID‐19: Results of a screening study for deep vein thrombosis , 2020, Research and Practice in Thrombosis and Haemostasis.

[2]  G. Raskob,et al.  Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness , 2018, The New England journal of medicine.

[3]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[4]  G. Gartlehner,et al.  [GRADE: Evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. , 2018, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[5]  R. Yusen,et al.  The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification , 2017, TH Open.

[6]  P. Prandoni,et al.  Scoring Systems for Estimating Risk of Venous Thromboembolism in Hospitalized Medical Patients , 2017, Seminars in Thrombosis and Hemostasis.

[7]  N. Kucher,et al.  Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. , 2017, Thrombosis and haemostasis.

[8]  D. D. De Silva,et al.  Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. , 2017, International angiology : a journal of the International Union of Angiology.

[9]  Alonso Carrasco-Labra,et al.  GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. , 2017, Journal of clinical epidemiology.

[10]  V. Chopra,et al.  Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. , 2016, The American journal of medicine.

[11]  T. McGinn,et al.  External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients , 2016, Thrombosis and Haemostasis.

[12]  Elie A Akl,et al.  GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. , 2016, Journal of clinical epidemiology.

[13]  G. Guyatt,et al.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines , 2016, British Medical Journal.

[14]  Gordon H Guyatt,et al.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction , 2016, British Medical Journal.

[15]  G. Raskob,et al.  The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE , 2016, Thrombosis and Haemostasis.

[16]  B. Wiens,et al.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. , 2016, The New England journal of medicine.

[17]  J. Collen,et al.  Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. , 2016, Chest.

[18]  Compression stockings for preventing deep vein thrombosis in airline passengers. , 2016, The Cochrane database of systematic reviews.

[19]  J. Bosch,et al.  Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis , 2016, Journal of Thrombosis and Thrombolysis.

[20]  Holger J Schünemann,et al.  Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. , 2015, Annals of internal medicine.

[21]  J. Kai,et al.  A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. , 2015, Health technology assessment.

[22]  P. Sandercock,et al.  The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. , 2015, Health technology assessment.

[23]  A. Gruber,et al.  Excess of heme induces tissue factor-dependent activation of coagulation in mice , 2015, Haematologica.

[24]  M. Tirani,et al.  [Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise]. , 2015, Recenti progressi in medicina.

[25]  D. Kendoff,et al.  Are patients with preoperative air travel at higher risk for venous thromboembolism following primary total hip and knee arthroplasty? , 2015, Technology and health care : official journal of the European Society for Engineering and Medicine.

[26]  G. Guyatt,et al.  Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. , 2014, JAMA.

[27]  A. Eichorn,et al.  External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System , 2014, Journal of the American Heart Association.

[28]  G. Guyatt,et al.  Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study. , 2014, Journal of clinical epidemiology.

[29]  V. Chopra,et al.  Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study. , 2014, JAMA internal medicine.

[30]  H. Büller,et al.  The incidence of venous thromboembolism in commercial airline pilots: a cohort study of 2630 pilots , 2014, Journal of thrombosis and haemostasis : JTH.

[31]  R. Joshi,et al.  Thrombo-prophylaxis in acutely ill medical and critically ill patients , 2014, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[32]  R. Berger,et al.  Risk of symptomatic venous thromboembolism associated with flying in the early postoperative period following elective total hip and knee arthroplasty. , 2014, The Journal of arthroplasty.

[33]  J. Gurwitz,et al.  Venous thromboembolism in older adults: A community-based study. , 2014, The American journal of medicine.

[34]  A. Cohen,et al.  Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). , 2014, The Cochrane database of systematic reviews.

[35]  H. Büller,et al.  The risk of venous thrombosis after air travel: contribution of clinical risk factors , 2014, British journal of haematology.

[36]  A. Mebazaa,et al.  D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial , 2014, Journal of thrombosis and haemostasis : JTH.

[37]  Romina Brignardello-Petersen,et al.  Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise , 2014, Canadian Medical Association Journal.

[38]  D. Aujesky,et al.  Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism , 2013, Thrombosis and Haemostasis.

[39]  L. Jeyaseelan,et al.  Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis. , 2013, The Journal of the Association of Physicians of India.

[40]  J. Stephenson,et al.  Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. , 2013, Thrombosis research.

[41]  D. Cook,et al.  Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials* , 2013, Critical care medicine.

[42]  F. Violi,et al.  Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux , 2013 .

[43]  J. Schein,et al.  Incidence of venous thromboembolism in nursing home residents. , 2013, Journal of the American Medical Directors Association.

[44]  R. Hull,et al.  Venous Thromboembolism in Elderly High-Risk Medical Patients , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[45]  M. Cushman,et al.  Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study , 2013, Journal of thrombosis and haemostasis : JTH.

[46]  P Prandoni,et al.  Prevention and treatment of venous thromboembolism--International Consensus Statement. , 2013, International angiology : a journal of the International Union of Angiology.

[47]  A. Mebazaa,et al.  Rivaroxaban for thromboprophylaxis in acutely ill medical patients. , 2013, The New England journal of medicine.

[48]  Elie A Akl,et al.  GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.

[49]  F. Rosendaal,et al.  Pregnancy and travel-related thromboembolism. , 2013, Thrombosis research.

[50]  D. Mukherjee,et al.  Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? , 2012, Journal of thrombosis and haemostasis : JTH.

[51]  S. Cannegieter Travel-related thrombosis. , 2012, Best practice & research. Clinical haematology.

[52]  Günter Ollenschläger,et al.  Guidelines International Network: Toward International Standards for Clinical Practice Guidelines , 2012, Annals of Internal Medicine.

[53]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[54]  J. Brecht,et al.  Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients , 2012, PharmacoEconomics.

[55]  C. Cimminiello,et al.  Low-molecular-weight heparin and mortality in acutely ill medical patients. , 2011, The New England journal of medicine.

[56]  S. Goldhaber,et al.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. , 2011, The New England journal of medicine.

[57]  Timothy J Wilt,et al.  Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline , 2011, Annals of Internal Medicine.

[58]  P. Shekelle,et al.  Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians , 2011, Annals of Internal Medicine.

[59]  L. Lynd,et al.  Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients—A Pharmacoeconomic Analysis , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[60]  W. Zeng,et al.  [The efficacy of intermittent pneumatic compression in the prevention of venous thromboembolism in medical critically ill patients]. , 2011, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[61]  A. Turpie,et al.  Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.

[62]  P. Pronovost,et al.  Are Sequential Compression Devices Commonly Associated With In-Hospital Falls? A Myth-Busters Review Using the Patient Safety Net Database , 2011, Journal of patient safety.

[63]  Monica Acciarresi,et al.  Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta‐analysis of controlled studies , 2011, Journal of thrombosis and haemostasis : JTH.

[64]  G. Guyatt,et al.  Dalteparin versus unfractionated heparin in critically ill patients. , 2011, The New England journal of medicine.

[65]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[66]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[67]  A. Turpie,et al.  Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. , 2011, Chest.

[68]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[69]  S. Greenfield,et al.  COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES , 2011 .

[70]  H. Riess,et al.  An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN , 2010, Expert opinion on pharmacotherapy.

[71]  P. Prandoni,et al.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.

[72]  M. Monreal,et al.  Prolonged travel and venous thromboembolism findings from the RIETE registry. , 2010, Thrombosis research.

[73]  E. Vicaut,et al.  Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility , 2010, Annals of Internal Medicine.

[74]  H. Riess,et al.  A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study , 2010, Journal of thrombosis and haemostasis : JTH.

[75]  G. Guyatt,et al.  The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution , 2010, Annals of Internal Medicine.

[76]  E. Tangalos,et al.  Thrombotic risk and immobility in residents of long-term care facilities. , 2010, Journal of the American Medical Directors Association.

[77]  David B. Resnik,et al.  Conflict of Interest in Medical Research, Education, and Practice , 2010, Environmental Health Perspectives.

[78]  P. Sandercock,et al.  Physical Methods for Preventing Deep Vein Thrombosis in Stroke , 2005, The Cochrane database of systematic reviews.

[79]  P. Perel,et al.  Thromboprophylaxis for trauma patients. , 2010, The Cochrane database of systematic reviews.

[80]  H. Forta,et al.  Prevention of Deep Venous Thrombosis and Pulmonary Embolism in Patients With Acute Intracerebral Hemorrhage , 2009, The neurologist.

[81]  M. Galinski,et al.  Gender as a risk factor for pulmonary embolism after air travel , 2009, Thrombosis and Haemostasis.

[82]  H. Schünemann,et al.  An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. , 2009, American journal of respiratory and critical care medicine.

[83]  D. Mozaffarian,et al.  Meta-analysis: Travel and Risk for Venous Thromboembolism , 2009, Annals of Internal Medicine.

[84]  J. Kline,et al.  Risk of thromboembolism varies, depending on category of immobility in outpatients. , 2009, Annals of emergency medicine.

[85]  P. Sandercock,et al.  Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial , 2009, The Lancet.

[86]  A. Amin,et al.  Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis , 2009, Thrombosis and Haemostasis.

[87]  K. Shojania,et al.  How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. , 2009, Journal of hospital medicine.

[88]  F. Rosendaal,et al.  Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. , 2009, Blood.

[89]  R. Nieuwland,et al.  Elevated platelet and leukocyte response to oral bacteria in periodontitis , 2009, Journal of thrombosis and haemostasis : JTH.

[90]  A. Shorr,et al.  Venous thromboembolism in critically ill patients , 2008, Thrombosis and Haemostasis.

[91]  J. Benner,et al.  Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism , 2008, Thrombosis and Haemostasis.

[92]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[93]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[94]  J. Eikelboom Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention , 2008 .

[95]  J. Douketis,et al.  Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta‐analysis , 2008, Journal of thrombosis and haemostasis : JTH.

[96]  Samuel Z Goldhaber,et al.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.

[97]  F. Rosendaal,et al.  Minor injuries as a risk factor for venous thrombosis. , 2008, Archives of internal medicine.

[98]  J. Jansson,et al.  Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta‐analysis , 2007, Journal of internal medicine.

[99]  P. Sandercock,et al.  Anticoagulants for acute ischaemic stroke. , 2008, The Cochrane database of systematic reviews.

[100]  H. Büller,et al.  Travel and venous thrombosis: a systematic review , 2007, Journal of internal medicine.

[101]  J. Donovan,et al.  Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. , 2007, Clinical therapeutics.

[102]  H. Krum,et al.  Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.

[103]  P Duclos,et al.  World Health Organization and International Travel and Health. , 2007, Travel medicine and infectious disease.

[104]  C. Kase,et al.  The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison , 2007, The Lancet.

[105]  J. Douketis,et al.  Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.

[106]  A. Shorr,et al.  Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[107]  G. Agnelli,et al.  What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? , 2007, Thrombosis research.

[108]  A. Folsom,et al.  Frailty and risk of venous thromboembolism in older adults. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[109]  A Eisinga,et al.  Compression stockings for preventing deep vein thrombosis in airline passengers. , 2006, The Cochrane database of systematic reviews.

[110]  Mir S. Siadaty,et al.  Air Travel and Venous Thromboembolism: A Systematic Review , 2007, Journal of General Internal Medicine.

[111]  M. Stokes,et al.  Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients , 2006, Thrombosis journal.

[112]  Luci K. Leykum,et al.  Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient. , 2006, Journal of hospital medicine.

[113]  M. Perpiñá-Tordera,et al.  Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa , 2006 .

[114]  D. Nauffal-Manzur,et al.  [Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease?]. , 2006, Archivos de bronconeumologia.

[115]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[116]  H. Diener,et al.  Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial , 2006, Stroke.

[117]  I. Mahé,et al.  Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study , 2005, European Journal of Clinical Pharmacology.

[118]  P. Stein,et al.  Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. , 2005, The American journal of cardiology.

[119]  G. Velmahos,et al.  Electrostimulation for the prevention of deep venous thrombosis in patients with major trauma: a prospective randomized study. , 2005, Surgery.

[120]  S. Sansgiry,et al.  Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. , 2005, The American journal of managed care.

[121]  E. Voth,et al.  Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage , 1988, Klinische Wochenschrift.

[122]  G. Guyatt,et al.  Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group , 2004, BMC health services research.

[123]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[124]  H. Yanar,et al.  Venous Thromboembolism Prophylaxis after Head and Spinal Trauma: Intermittent Pneumatic Compression Devices Versus Low Molecular Weight Heparin , 2004, World Journal of Surgery.

[125]  A. Lloyd,et al.  Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients , 2004, Pharmacy World and Science.

[126]  Paul Enright,et al.  Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. , 2004, The American journal of medicine.

[127]  S. Cohn,et al.  Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma , 2003, The British journal of surgery.

[128]  Andrew D Oxman,et al.  Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[129]  C. Witt,et al.  Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. , 2003, American heart journal.

[130]  M. Kaste,et al.  Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind study , 2002, Acta neurologica Scandinavica.

[131]  L. Melton,et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.

[132]  J. Heit Venous Thromboembolism Epidemiology: Implications for Prevention and Management , 2002, Seminars in thrombosis and hemostasis.

[133]  A. Gafni,et al.  Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical Patients with Enoxaparin. , 2002, Canadian respiratory journal.

[134]  A. Nicolaides,et al.  Venous Thrombosis from Air Travel: The LONFLIT3 Study , 2002, Angiology.

[135]  P. Sandercock,et al.  Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfractionated Heparin for Acute Ischemic Stroke , 2005 .

[136]  A. Lloyd,et al.  Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients , 2001 .

[137]  F. Fagnani,et al.  Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[138]  S. Goldhaber,et al.  Low molecular weight heparin versus minidose unfractionated heparin for prophylaxis against venous thromboembolism in Medical Intensive Care Unit patients A randomized controlled trial , 2000 .

[139]  R. Pordes,et al.  Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. , 2000, American journal of respiratory and critical care medicine.

[140]  Y. Kupfer,et al.  Subcutaneous Heparin Prophylaxis Significantly Reduces The Incidence Of Venous Thromboembolic Events In The Critically Ill , 1999 .

[141]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[142]  B. Meyer Antithrombotic Drugs:Insights f rom Cardiology , 1998, Cerebrovascular Diseases.

[143]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[144]  J. Bergmann,et al.  A Multicenter Randomized Double-blind Study of Enoxaparin Compared with Unfractionated Heparin in the Prevention of Venous Thromboembolic Disease in Elderly In-patients Bedridden for an Acute Medical Illness , 1996, Thrombosis and Haemostasis.

[145]  M. Knudson,et al.  Use of low molecular weight heparin in preventing thromboembolism in trauma patients. , 1996, The Journal of trauma.

[146]  B. Gårdlund,et al.  Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases , 1996, The Lancet.

[147]  W. Schramm,et al.  The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. , 1996, Haemostasis.

[148]  A. Ahuja,et al.  Low-molecular-weight heparin for the treatment of acute ischemic stroke , 1995 .

[149]  P Landau,et al.  Deep vein thrombosis: prevention in stroke patients during rehabilitation. , 1995, Archives of physical medicine and rehabilitation.

[150]  C. Fisher,et al.  Effectiveness of Pneumatic Leg Compression Devices for the Prevention of Thromboembolic Disease in Orthopaedic Trauma Patients: A Prospective, Randomized Study of Compression Alone Versus no Prophylaxis , 1995, Journal of orthopaedic trauma.

[151]  J. Egberts,et al.  A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. , 1994, Age and ageing.

[152]  F. Lewis,et al.  Prevention of venous thromboembolism in trauma patients. , 1994, The Journal of trauma.

[153]  W. Fallon,et al.  Efficacy of deep venous thrombosis prophylaxis in trauma patients and identification of high-risk groups. , 1992, The Journal of trauma.

[154]  M. Gent,et al.  A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke , 1992, Annals of Internal Medicine.

[155]  M. Knudson,et al.  Thromboembolism following multiple trauma. , 1992, The Journal of trauma.

[156]  P. Sandset,et al.  A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. , 1990, Seminars in thrombosis and hemostasis.

[157]  A. Serradimigni,et al.  Prévention des thromboses veineuses profondes des membres inférieurs par une fraction d'héparine de très bas poids moléculaire (CY 222) chez des patients porteurs d'une hémiplégie secondaire à un infarctus cérébral: étude pilote randomisée (30 patients) , 1990 .

[158]  R. Khalil,et al.  [Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)]. , 1990, La Revue de medecine interne.

[159]  M. Prins,et al.  Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. , 1989, Haemostasis.

[160]  C. Ibarra-Pérez,et al.  Prevalence and Prevention of Deep Venous Thrombosis of the Lower Extremities in High-Risk Pulmonary Patients , 1988, Angiology.

[161]  A. Turpie,et al.  Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. , 1986, Annals of internal medicine.

[162]  M. M. Fukujima,et al.  Prevention of Deep Venous Thrombosis and Pulmonary Embolism , 1986, The Lancet.

[163]  S. McCarthy,et al.  Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. , 1986, Age and ageing.

[164]  C. Caulin,et al.  Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. , 1986, Haemostasis.

[165]  E. Salzman,et al.  Prevention of venous thromboembolism in unstable angina pectoris. , 1982, The New England journal of medicine.

[166]  A. Banerjee,et al.  Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics. , 1982, Age and ageing.

[167]  C. Forbes,et al.  Prevention of Deep Vein Thrombosis in Medical Patients by Low-Dose Heparin , 1981, Scottish medical journal.

[168]  C. Hawkey,et al.  LOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKE , 1977, The Lancet.

[169]  R. J. Tuttle,et al.  Small subcutaneous doses of heparin in prevention of venous thrombosis. , 1973, The New England journal of medicine.

[170]  C. Dolea,et al.  World Health Organization , 1949, International Organization.